Form 8-K - Current report:
SEC Accession No. 0001493152-26-025037
Filing Date
2026-05-22
Accepted
2026-05-22 16:30:23
Documents
17
Period of Report
2026-05-20
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K form8-k.htm   iXBRL 8-K 57589
2 EX-4.1 ex4-1.htm EX-4.1 121621
3 EX-4.2 ex4-2.htm EX-4.2 113505
4 EX-4.3 ex4-3.htm EX-4.3 113532
5 EX-4.4 ex4-4.htm EX-4.4 113532
6 EX-10.1 ex10-1.htm EX-10.1 272983
  Complete submission text file 0001493152-26-025037.txt   1163964

Data Files

Seq Description Document Type Size
7 XBRL SCHEMA FILE aktx-20260520.xsd EX-101.SCH 3822
8 XBRL DEFINITION FILE aktx-20260520_def.xml EX-101.DEF 26702
9 XBRL LABEL FILE aktx-20260520_lab.xml EX-101.LAB 36863
10 XBRL PRESENTATION FILE aktx-20260520_pre.xml EX-101.PRE 25326
22 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 5047
Mailing Address 401 EAST JACKSON STREET SUITE 3300 TAMPA FL 33602
Business Address 401 EAST JACKSON STREET SUITE 3300 TAMPA FL 33602 (929) 274-7510
Akari Therapeutics Plc (Filer) CIK: 0001541157 (see all company filings)

EIN.: 981034922 | State of Incorp.: X0 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36288 | Film No.: 261014376
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)